Compare AbbVie Inc (ABBV) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI South Africa ETF — how do they compare? AbbVie Inc trades at $254.16 (market cap $449.91B), while iShares MSCI South Africa ETF trades at $62.52. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MSCI South Africa ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | EZA | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $81.60 |
52-Week Low | $184.85 | $52.86 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EZA trades at $64.63, up 0.98% on the day, but technical indicators signal a bearish trend with moving averages pointing lower. The stock faces resistance near $65 and has support at $63. A dividend of $1.43 is scheduled for payment on June 22, 2026. Recent news highlights South Africa's extended fuel tax cut, which may impact regional economic conditions relevant to the fund's holdings.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Risks include exposure to South African economic policies and commodity volatility. Investors should await updated financials for a clearer valuation picture, as current metrics are unavailable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
